Triamcinolone Acetonid in Alopecia Areata

Phase 3

Recruiting

• Conditions: Other alopecia areata; L63.8; Alopecia Areata.

• Registration Number: IRCT20100314003566N10
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 March 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Alopecia areata patients with one or more patch lesions.
Patients 15 years and older
Patients who declare their full consent to participate in the study.
The duration of the disease is 3 to 12 months and there is no sign of new hair growth at the site of the lesion.

Exclusion Criteria

Children
Background or presence of skin diseases such as psoriasis, seborrheic dermatitis, and malignancy and infection at the site
Patients with malignancy and blood dyscrasia
Pregnant and lactating women
Patients with mental retardation and physical disability
Patients who have received topical or systemic corticosteroids and topical treatments in alopecia areata or immunosuppressive drugs over the past month.
People with autoimmune, type I diabetes, etc.
No seizure

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber and Length of new hear at lesion site. Timepoint: Monthly. Method of measurement: Clinical Examination of Number and Length of new hear at lesion site.

Secondary Outcome Measures

Name	Time	Method
ew Hear Growth Rate. Timepoint: Monthly. Method of measurement: Clinical Examination of New Hear Growth Rate on Injection Site.